who treatment guidelines for drug-resistant tuberculosis ?

Description

https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/

WHO consolidated guidelines on drug-resistant tuberculosis …
https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/
Between 2011 and 2018, WHO has developed and issued evidence-based policy recommendations on the treatment and care of patients with DR-TB. These policy recommendations have been presented in several WHO documents and their associated annexes, including the WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update, issued by WHO in December 2018. The policy recommendations in each of these guidelines have been developed by WHO-convened Guideline Development …

https://www.who.int/publications-detail-redirect/9789241549639

WHO treatment guidelines for drug-resistant tuberculosis …
https://www.who.int/publications-detail-redirect/9789241549639
In November 2015, the World Health Organization (WHO) convened a meeting of a Guideline Development Group (GDG) for the update of policy recommendations on the treatment of drug-resistant TB. The GDG was composed of a multidisciplinary group of tuberculosis (TB) and drug-resistant TB experts external to WHO. Before the meeting, the members of the GDG and the WHO Guideline Steering Committee had decided upon the priority questions in the treatment and care of patients with drug …

https://www.who.int/tb/areas-of-work/drug-resistant-tb/guideline-update/en/

WHO Guideline for the Treatment of Drug-resistant Tuberculosis
https://www.who.int/tb/areas-of-work/drug-resistant-tb/guideline-update/en/
The World Health Organization is in the process to update the WHO Guideline for the treatment of drug-resistant tuberculosis. The Guideline will limit its scope to the following dimensions of treatment and care of drug-resistant tuberculosis (DR-TB) patients: The optimal combination of TB drugs to treat patients with drug-resistant TB*;

https://pubmed.ncbi.nlm.nih.gov/28905529/

WHO Treatment Guidelines for Drug-Resistant Tuberculosis …
https://pubmed.ncbi.nlm.nih.gov/28905529/
Despite progress made in tuberculosis control worldwide, the disease burden and treatment outcome of multidrug-resistant tuberculosis (MDR-TB) patients have remained virtually unchanged. In 2016, the World Health Organization released new guidelines for the management of MDR-TB. The guidelines are intended to improve detection rate and treatment outcome for MDR-TB through novel, rapid molecular testing and shorter treatment regimens. Key changes include the introduction of a new, shorter MDR …

https://apps.who.int/iris/bitstream/handle/10665/250125/9789241549639-eng.pdf;sequence=1

WHO treatment guidelines for drug- resistant tuberculosis
https://apps.who.int/iris/bitstream/handle/10665/250125/9789241549639-eng.pdf;sequence=1
WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. October 2016 revision. Contents: Web Annex 4: GRADE tables – Web Annex 5: Evidence to decision tables – Web Annex 6: Summaries of unpublished data used for the recommendations 1.Tuberculosis, Multidrug-Resistant – drug therapy. 2.Antitubercular Agents. 3.Guideline. I.World Health Organization.

https://www.who.int/publications-detail-redirect/9789240007048

WHO Consolidated Guidelines on Tuberculosis, Module 4 …
https://www.who.int/publications-detail-redirect/9789240007048
The present WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment – Drug-Resistant Tuberculosis Treatment includes a comprehensive set of WHO recommendations for the treatment and care of DR-TB. The document includes two new recommendations, one on the composition of shorter regimens and one on the use of the BPaL regimen (i.e. bedaquiline, pretomanid and linezolid). In addition, the consolidated guidelines include existing recommendations on treatment regimens for …

https://pdf.usaid.gov/pdf_docs/PBAAE970.pdf

PDF WHO treatment guidelines for drug- resistant tuberculosis
https://pdf.usaid.gov/pdf_docs/PBAAE970.pdf
Contents Appendix 4. GRADE tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 I. Shorter regimens for MDR-TB (PICO 3

https://www.who.int/tb/publications/2018/WHO_guidelines_isoniazid_resistant_TB/en/

WHO | WHO treatment guidelines for isoniazid-resistant …
https://www.who.int/tb/publications/2018/WHO_guidelines_isoniazid_resistant_TB/en/
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.

https://www.who.int/tb/publications/2010/9789241547833/en/

WHO | Guidelines for treatment of tuberculosis
https://www.who.int/tb/publications/2010/9789241547833/en/
This is fourth edition of Treatment of tuberculosis: guidelines, adhering fully to the new WHO process for evidence-based guidelines. Several important recommendations are being promoted in this new edition. First, the recommendation to discontinue the regimen based on just 2 months of rifampicin (2HRZE/6HE) and change to the regimen based on a …

https://apps.who.int/iris/bitstream/handle/10665/260494/9789241550079-eng.pdf;sequence=1

WHO treatment guidelines for isoniazid resistant tuberculosis
https://apps.who.int/iris/bitstream/handle/10665/260494/9789241550079-eng.pdf;sequence=1
6 Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis (WHO/HTM/TB/2014.11). Available from: http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809_eng.pdf. Geneva: World Health Organization. 2014.